Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq:MIST) announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A live and replay webcast of the 3:00 p.m. ET fireside chat will be available on Milestone's website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Market Reaction – MIST
Following this news, MIST has declined 8.73%, reflecting a notable negative market reaction. Our momentum scanner has triggered 11 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.57. This price movement has removed approximately $18M from the company's valuation. Trading volume is above average at 1.8x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
MIST is down 9.47% while key biotech peers like ACOG, GLSI and KYTX show positive moves (e.g., KYTX up 4.76%), pointing to a stock-specific dynamic rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Earnings and update | Neutral | -9.5% | First quarter 2026 financials and CARDAMYST commercial progress with clinical updates. |
| May 6 | Earnings date notice | Neutral | +4.8% | Announcement of Q1 2026 earnings release timing and investor call details. |
| Apr 10 | Registry launch news | Neutral | +0.5% | RESET-PSVT Phase 4 real-world registry initiation plan for CARDAMYST nasal spray. |
| Apr 7 | Conference presentation | Neutral | +5.9% | Participation in the 25th Annual Needham Virtual Healthcare Conference with webcast. |
| Apr 2 | Equity incentives | Neutral | +5.3% | Grant of 123,000 stock options to new hires under inducement plan. |
Recent history shows notable price moves around corporate updates and conference appearances, with both positive and negative reactions, indicating event-driven trading without a clear directional pattern.
Over the past six weeks, Milestone reported its first commercial CARDAMYST™ sales and Q1 2026 results on May 13, 2026, after pre-announcing the earnings date on May 6. Earlier, it launched the RESET-PSVT real-world registry and highlighted an FDA approval in December 2025. The company also announced participation in the Needham healthcare conference and disclosed inducement option grants. Against this backdrop, the new H.C. Wainwright BioConnect appearance continues a pattern of active investor engagement following key commercial and clinical milestones.
Regulatory & Risk Context
An effective S-3 shelf filed on May 13, 2026 permits offerings of up to $300,000,000 in various securities, including a Controlled Equity Sales Agreement for up to $100,000,000 of common shares with Cantor Fitzgerald & Co. As of the latest data, usage count is 0, and specific issuances would be detailed in future prospectus supplements.
Market Pulse Summary
This announcement highlights Milestone’s participation in the H.C. Wainwright BioConnect conference on May 19, 2026, with a webcast at 3:00pm ET and replay access for about 90 days. It extends a recent run of investor outreach following Q1 2026 financials and early CARDAMYST commercialization data. In parallel, a new S-3 shelf for up to $300,000,000 in securities, including a $100,000,000 equity sales agreement, adds financing flexibility that investors may monitor alongside clinical and commercial updates.
AI-generated analysis. Not financial advice.
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.
A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please contact your H.C. Wainwright representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
